Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.87 +0.64 (+1.10%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
66 67 Next >
High-yield, low-beta value plays for buy-and-hold investors
High-yield stocks that trade at a value and come with a lower-than-average beta can help mitigate portfolio volatility and boost returns over time. 
Via MarketBeat
Topics Economy
Exposures Economy
Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates
Share repurchases have slowed in 2023, partly due to the 1% tax. Here are three buybacks partially paid for with debt offerings. 
Via InvestorPlace
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
There's a lot more at stake than bragging rights. 
Via The Motley Fool
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Is NYSE:BMY suited for dividend investing?
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing? 
Via Chartmill
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
From Bristol Myers Squibb
Via Business Wire
3 No-Brainer Stocks to Buy With $500 Right Now
A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
From Bristol Myers Squibb
Via Business Wire
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
From Bristol Myers Squibb
Via Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO
Via Benzinga
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its... 
Via Talk Markets
Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook
Bristol-Myers Squibb Co (NYSE: BMY) shares are trading lower on continuous weakness following the disappointing Q3 earnings and a downward revision to the  
Via Benzinga
Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results
Bristol Myers Squibb & Co (NYSE: BMY) reported better-than-expected earnings for its third quarter. 
Via Benzinga
Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review
Microsoft, Google, Amazon and Meta led big earnings. 
Via Investor's Business Daily
Bristol Myers Squibb (BMY) Q3 2023 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
US Stocks Mixed; Bristol Myers Posts Upbeat Earnings
U.S. stocks traded mixed this morning, following the release of several economic reports. Following the market opening Thursday, the Dow traded up 0.10% to 33,069.66 while the NASDAQ fell 0.24% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Squibb's Revlimid Sales Plunge 41%, but Opdivo and Eliquis Boost Q3, Stock Dips
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q3 revenues of $10.966 billion declined 2% Y/Y, or 3% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line... 
Via Benzinga
Bristol Myers Skids 5% After Pushing Back A Key Sales Milestone By A Year
The company expects its new drugs to reach $10 billion in sales by 2026. 
Via Investor's Business Daily
Nasdaq Futures Plunge As Meta Warns Of Q4 Softness: GDP Data, Amazon Earnings On Investors' Radar Amid Market Mayhem
Stock futures are plunging after the mega-cap tech names haven't turned in the strong results that the markets had factored in. 
Via Benzinga
2 Absurdly Cheap Healthcare Stocks to Buy and Hold for Decades
You won't have to worry about paying a premium for either one of these stocks -- and they both pay a solid dividend. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.